Neurosurgery denied? We cite NASS, AANS/CNS, and the trial data they ignored.

Why neurosurgery denials are different

A denied neurosurgical procedure is rarely about money in the small sense — these are five- and six-figure operations on the central nervous system. Insurers know that, which is why their denial letters lean heavily on policy language, conservative-care thresholds, and "investigational" labels for newer technologies (CADR, flow diversion, certain shunt designs).

The good news: insurers' own medical policies cite the same authoritative bodies neurosurgeons publish in. NASS Coverage Recommendations, AANS/CNS Joint Guidelines, FDA IDE pivotal trials, and the SPORT/ISAT data sets — when correctly invoked — almost always meet or exceed the insurer's own coverage criteria. A successful appeal turns the policy back on the policy.

This guide walks through the most common denial categories for spine and cranial procedures, exactly which evidence to cite, and the structure of an effective appeal letter.

The denial categories you'll actually see

Across thousands of neurosurgical denials, five reasons account for ~85% of all rejections:

1. "Conservative care insufficient" — typically requires 6 weeks supervised PT + medication trial + ≥1 epidural steroid injection (ESI) for elective spine surgery. Waived for cauda equina, progressive motor deficit, severe myelopathy, or oncologic emergency.

2. "Instability not documented" — for lumbar fusion, requires translation in millimeters or angulation in degrees on flexion-extension X-rays. Most insurers cite ≥4mm translation or ≥10° angulation as the threshold.

3. "Investigational / experimental" — most often hits cervical artificial disc replacement (especially 2-level), flow diversion devices, certain shunt configurations, and newer minimally-invasive fusion approaches.

4. "Step therapy not exhausted" — for tumor cases, this usually means "try stereotactic radiosurgery first." For aneurysms, "monitor instead." For Chiari, "try medications first."

5. "Documentation insufficient" — almost always means: no imaging measurements, no neuro exam, no functional disability score (mJOA, Nurick, ODI, NDI), no operative tumor board / multidisciplinary review note.

Each one has a specific counter — and they're not subtle.

Conservative care: build a logbook insurers can't dismiss

Insurers need three things in writing:

1. Physical therapy with start date, sessions, provider, and a quantitative outcome — Oswestry Disability Index (ODI) for low back, Neck Disability Index (NDI) for cervical. Every PT discharge note has these. Ask for them.

2. Medication trial — drug, dose, duration, response, side effects. NSAIDs, gabapentin/pregabalin, SNRI/TCA, sometimes a short opioid trial. "Patient tried Motrin" doesn't cut it; "Naproxen 500mg BID × 6 weeks → 20% pain reduction, gastritis on week 5" does.

3. Epidural steroid injection — date, level, % relief, duration. One ESI with <30% relief or two with <50% sustained relief is the standard threshold for moving to surgical decompression.

For cauda equina syndrome, progressive motor deficit (MRC ≤4/5), severe cervical myelopathy (mJOA ≤12), ruptured aneurysm, or rapidly progressive tumor — conservative care is contraindicated and the appeal letter must say so explicitly. Cite the AANS/CNS Cervical Spondylotic Myelopathy Guideline and SPORT data for non-emergent cases.

Lumbar discectomy: the SPORT trial is your friend

The Spine Patient Outcomes Research Trial (Weinstein, NEJM 2006) randomized 501 patients with imaging-confirmed lumbar disc herniation and persistent radiculopathy to surgery or non-operative management. The surgical cohort had significantly better pain, function, and disability outcomes at 3 months — sustained out to 4 years. Even with substantial cross-over (which biased toward null), surgery won.

For UHC, Aetna, Cigna, and BCBS denials of lumbar microdiscectomy, the appeal letter should:

• Cite SPORT lumbar disc herniation by name and reference (Weinstein NEJM 2006;354:2257–70 + Weinstein JAMA 2006;296:2451–9 4-year follow-up).
• Quote the insurer's own policy criteria: "imaging-confirmed disc herniation with corresponding radiculopathy" and "failure of 6 weeks supervised conservative care or progressive deficit."
• Submit the MRI report with herniation size in mm + nerve-root contact + radiologist signature.
• Submit the EMG/NCS if neurologic deficit present.
• Submit the conservative-care log per the section above.
• Reference AANS/CNS Joint Guideline for Treatment of Adult Patients With Lumbar Disc Herniation.

When cauda equina syndrome is present (saddle anesthesia, urinary retention, bilateral weakness), the appeal goes urgent / expedited and cites the standard-of-care window of <48h to surgical decompression — no insurer policy survives that argument.

Lumbar fusion: instability is everything

Cigna's Coverage Policy 0051 is the most-cited fusion policy and it sets the bar all other insurers loosely follow: lumbar fusion requires either (a) Grade ≥I spondylolisthesis with documented instability, OR (b) translation ≥4mm or angulation ≥10° on flexion-extension X-rays. Without those measurements written into the radiology report, you will be denied.

The successful fusion appeal includes:

• Flexion-extension lumbar X-rays with explicit measurements (radiologist must annotate translation in mm and angulation in degrees).
• NASS Coverage Recommendations for lumbar fusion (these are publicly available and mirror Cigna CCP 0051).
• SPORT degenerative spondylolisthesis (Weinstein NEJM 2007) — fusion superior to non-op at 4 years.
• Conservative care log.
• For multi-level: explicit imaging correlation per level + functional impairment justifying each level.
• Smoking cessation documentation 6+ weeks pre-op (many insurers now require this).

Cervical artificial disc replacement: the multi-level battle

Single-level CADR has been FDA-approved since 2007 (Prestige) and is broadly covered. Two-level CADR is where insurers still try to deny.

The cleanest counter:

• Mobi-C 2-level FDA approval — August 7, 2013 (FDA PMA P110002 supplement). This is the only US 2-level cervical TDR on-label.
• Davis JNS Spine 2015 — 7-year follow-up of the Mobi-C 2-level IDE: superior NDI, overall success, and reoperation rate vs ACDF.
• Prestige LP IDE 7-year (Burkus JNS Spine 2014) — cervical TDR non-inferior to ACDF, lower adjacent-segment reoperation.
• AANS/CNS Joint Section Guideline — supports CADR as alternative to ACDF for selected single- and multi-level cervical radiculopathy.

Anthem SURG.00139 specifically lists the FDA-approved devices and their on-label indications. Quote it back.

Craniotomy for tumor: the tumor board note matters more than the imaging

Insurers denying craniotomy for symptomatic brain tumor almost always cite "try SRS first." That argument is wrong for most surgical cases:

• Tumors >3cm are not preferred SRS candidates due to peritumoral edema risk and lower 1-year local control.
• Symptomatic mass effect / midline shift requires decompression, which SRS can't provide.
• Pathology unknown — SRS without tissue diagnosis is unacceptable for most aggressive lesions; resection provides histopathology + WHO grading + molecular markers (IDH, MGMT, 1p/19q) that drive adjuvant therapy.
• NCCN CNS Tumors Guideline explicitly recommends maximal safe resection for newly-diagnosed high-grade glioma, accessible meningioma, and most metastases >3cm or symptomatic.

The tumor-board note (multidisciplinary review with neurosurgery + neuro-oncology + radiation oncology) carries more weight in an appeal than any single specialist's opinion. Many insurers explicitly require it.

For GBM specifically, cite the Stupp protocol (NEJM 2005, 5-yr follow-up NEJM 2009) — gross total resection followed by concurrent RT/TMZ then adjuvant TMZ is the standard of care. Anything that delays resection delays the entire protocol.

Aneurysm clipping vs coiling: ISAT didn't end the debate

The International Subarachnoid Aneurysm Trial (Molyneux Lancet 2002, 2005, 2015 long-term) randomized 2,143 patients with ruptured aneurysms suitable for both clipping and coiling. Coiling had better 1-year independent-survival outcomes; that benefit persisted at 10 years for ISAT-suitable aneurysms. The Barrow Ruptured Aneurysm Trial (BRAT, McDougall JNS 2012, 2018) confirmed comparable outcomes in selected populations with anterior-circulation aneurysms.

For ruptured aneurysms the choice is anatomy-driven (dome:neck ratio, location, branch-vessel involvement) and not "either/or." Cite both ISAT and BRAT.

For unruptured aneurysms, the AHA/ASA 2015 guideline (Stroke 2015;46:2368–400) drives coverage decisions. Decision factors: aneurysm size, location, dome/neck morphology, family history, smoking, hypertension, prior SAH, and PHASES score. Symptomatic / sentinel-headache / mass-effect aneurysms warrant treatment regardless of size.

For flow diversion (Pipeline, Surpass), the PUFS trial supports >7mm wide-neck aneurysms in the internal carotid as the on-label indication; ASPIRE and CONFIDENCE expand evidence.

VP shunt and shunt revision: the imaging is the argument

Shunt placements get denied less often than revisions. The successful revision appeal:

• Imaging measurements: Evans index (>0.30), callosal angle (<90° in NPH), third-ventricle width.
• Symptoms: for NPH, the Hakim triad (gait, cognition, urinary). For pediatric/young hydrocephalus, headache + emesis + papilledema + 6th-nerve palsy.
• Shunt malfunction documentation: obstructed catheter on shunt-flow imaging, mechanical fracture on plain films, infection markers (CSF cell count, culture), overdrainage on imaging (slit ventricles).
• Programmable shunt rationale: literature on reduced repeat OR rates (Browd Neurosurgery 2006) — programmable shunts allow non-invasive pressure adjustment, avoiding multiple surgeries.

Hydrocephalus Association and International Society of Hydrocephalus Disorders consensus statements support both initial placement and revision when imaging + clinical correlation is present.

Chiari decompression: the 5mm threshold isn't absolute

Most insurer policies cite tonsillar descent ≥5mm below the foramen magnum as the imaging threshold for posterior-fossa decompression. Symptomatic Chiari with cough-induced headache, syrinx, brainstem compression, or progressive cranial-nerve deficit can warrant surgery even at 3–5mm descent — and the AANS/CNS Pediatric Chiari Guideline (which provides the evidence framework most adult cases extrapolate from) supports this.

The successful Chiari appeal documents:

• Tonsillar descent in mm (radiologist measurement).
• Syrinx if present (level, length, growth on serial imaging).
• Symptom log: cough headache, Valsalva-induced headache, dysphagia, sleep apnea, occipital pain pattern.
• Failed conservative trial (NSAIDs, posture, neurology evaluation).
• For pediatric cases, age + growth trajectory.

Cite Sahuquillo + Aliaga JNS 2018 outcome series and the AANS/CNS guideline. Quality-of-life literature (Mueller Neurosurgery 2013) on post-decompression headache resolution carries weight.

The peer-to-peer call: prepare for it before you write the appeal

Most insurer denials carry a deadline (often 14 days) for a peer-to-peer review with the medical director. Demand it explicitly in your appeal. The peer-to-peer rules:

• The insurer must provide a same-specialty reviewer (neurosurgeon, not internist or anesthesiologist).
• Schedule it within the deadline; document who you spoke to.
• Bring three things to the call: the imaging measurements, the conservative-care log, and the specific guideline citation that the insurer's own policy mirrors.

A successful peer-to-peer often overturns the denial without a formal written appeal. Even when it doesn't, the call generates a paper trail that strengthens the next-level appeal.

A note on letter length and tone

A neurosurgical appeal should be 1.5 to 2 pages — long enough to address the denial point-by-point, short enough that the medical director will actually read it. Structure:

1. Header with member ID, claim #, procedure, CPT.

2. Diagnosis + ICD-10 + duration + imaging correlate (1 paragraph).

3. Conservative care log (concise table or list).

4. Neurologic exam findings (1 paragraph, MRC + reflexes + pathologic signs + functional score).

5. Address the denial reason directly — quote the insurer's own coverage criteria, demonstrate each is met, cite the controlling guideline + pivotal trial.

6. Closing — request overturn within deadline, demand peer-to-peer with same-specialty reviewer.

Tone is professional, firm, evidence-driven. Avoid emotional language. The medical director responds to evidence and policy citations, not adjectives.

When to escalate

If the first-level appeal fails, the next step depends on plan type:

• Self-funded ERISA plans — second-level internal appeal, then external review (binding under ACA §2719).
• Fully-insured plans (state-regulated) — state-mandated external review (varies by state, often through the state insurance department).
• Medicare Advantage — Independent Review Entity (IRE) review, then ALJ hearing.
• Medicaid — state Fair Hearing.

Each level has its own deadline (usually 60–180 days from the prior denial). A neurosurgery practice's appeals coordinator should track all of them.

What good looks like

A successful neurosurgical appeal letter:

• Quotes the insurer's own policy by name and number.
• Cites NASS Coverage Recommendations + AANS/CNS Joint Guideline + FDA IDE pivotal trial + NEJM SPORT/ISAT/Stupp by name and PMID/DOI where appropriate.
• Includes imaging measurements (mm, degrees, Evans index, mJOA, ODI) — not adjectives.
• Documents conservative-care exhaustion or its medical contraindication.
• Demands peer-to-peer with a same-specialty neurosurgeon.
• Stays within 2 pages.

Most denials reverse on first appeal when these elements are present. The work is in the documentation — once the chart contains the right measurements and references, drafting the letter is mechanical.